Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. - Test2 - elhamkhani - TriplyDB

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

http://www.wikidata.org/entity/Q33968358

about

Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women.Viral hepatitis in HIV infection.Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis New approaches in the management of chronic hepatitis B: role of tenofovir.Emerging drugs for hepatitis B.Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis Review of tenofovir-emtricitabine.Management of chronic hepatitis B: consensus guidelines Towards the elimination and eradication of hepatitis B.Current treatment of HIV/hepatitis B virus coinfection.Experience with tenofovir disoproxil fumarate for antiretroviral therapy.Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.Management of hepatic complications in HIV-infected persons.Immune restoration diseases reflect diverse immunopathological mechanisms.Future directions in the treatment of HIV-HBV coinfection.The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.Tenofovir for the treatment of hepatitis B virus.HIV/hepatitis B virus co-infection: current challenges and new strategies.Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort Management of HIV and hepatitis virus coinfection.Adefovir dipivoxil in chronic hepatitis B: history and current uses.Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.Current antiviral therapies for chronic hepatitis B.

P2860

Q24187530-C40FFF52-FE00-48EF-BB88-B78DBAE643AA Q26781379-12CD2EBA-CC8F-4AAD-BCE8-CEA9A41ABCA5 Q30440211-9C8D171B-E99A-458A-A0CA-3F31D6628681 Q33650105-16B17F3B-4636-4004-97C0-CC1CC49DA05A Q33819098-3DC43AAE-43F7-4858-A1A0-28A86E302906 Q34024622-6F0A8973-05EB-4EA5-AB6F-58A04FA5BFC0 Q34024728-52E63354-3A2E-4285-AA0E-83A983F36612 Q34080934-0B845579-5DF7-4CA3-84A9-CDE64F46C586 Q34086980-99577B5E-5049-4C8B-B53A-29A2C180CA2F Q34120399-4B97A5CE-3E59-437B-B7A5-D9610CC4BDAF Q34212799-27E4343F-B9E3-41B3-B8E6-7A5C6C1409F1 Q34213161-A88E50F9-B5C8-4AC1-8CE6-1C94F8AC3C3D Q34405008-67B6CC2F-03A7-4A4E-85EB-0391A4C527B7 Q34409132-5B11C4BD-D537-417D-B456-154D34AA8769 Q34712961-4061EF18-F57C-4A49-BD4B-89752460CD05 Q34847029-A97EFD82-56B6-41D6-90AF-F780810CA236 Q35026531-C7F70F67-E128-4640-A4E2-0C7B2014FEBE Q35359369-664A8847-6810-49B9-A9E0-1256196C01E1 Q35433965-B0F93F02-9BBD-4E0A-9B1F-B94296F80F77 Q35530299-A93BA675-AAE3-4DCA-9695-D42654045698 Q36276597-809AC3DE-7CAB-4A5B-9DF7-1456E6795D5E Q36492635-29D47D33-89D6-4899-998D-53E328DF1687 Q36663686-96E597AA-CB73-4BD1-AFFA-7B433A92164E Q36849343-4E8DDEEE-72A5-4124-9B46-217A4D674A2E Q37098214-3782F988-0704-4032-809E-2283F1EFE339 Q37138048-1C71C403-3FF2-4AC6-816E-0F59554C04EA Q37142078-8CB9902A-AB79-4550-A5D0-05032202EA2A Q37149701-49526310-8A2B-4514-B020-589E1163A221 Q37151303-A95A8067-7E4D-41E0-AB1C-66EA227D4971 Q37409995-4E96CDE5-A1FF-40D1-B45A-FB05873ACF83 Q37439933-8B70168A-F0FB-440C-B392-B921378152A3 Q37518294-20EA063D-97CB-4EC8-A52D-3AD5D9CD68F8 Q37605886-62007B87-4FA6-40CC-8BCD-0BEF162142D3 Q37630062-41EEDB20-F81A-4690-AA8C-C8397DCFC018 Q37632321-335BAD62-9094-4947-A6C2-658A5A9B6A5E Q37694907-340F3B3D-4D15-4870-85CF-D959C670F00D Q37772508-863051C0-6D29-492B-8479-FA8331BC6FF2 Q37975548-FCD44E97-4AB1-4BCF-B8CC-1ACDAFE8EBA2 Q39859839-FAE75A75-76CB-4BC9-AB9A-3CD54155EEB5 Q40096242-3FD22DEF-BA38-4FD7-B8DB-9165A0F35EF7

P2860

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

http://www.wikidata.org/entity/Q33968358

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Randomized controlled study of ...... and HIV infection: ACTG A5127.

@ast

Randomized controlled study of ...... and HIV infection: ACTG A5127.

@en

type

label

Randomized controlled study of ...... and HIV infection: ACTG A5127.

@ast

Randomized controlled study of ...... and HIV infection: ACTG A5127.

@en

prefLabel

Randomized controlled study of ...... and HIV infection: ACTG A5127.

@ast

Randomized controlled study of ...... and HIV infection: ACTG A5127.

@en

P1433

Q33968358-92C0906C-215F-43E9-B4E3-BAE364EA4E6B

P1476

Q33968358-82C80F70-B79A-4797-8544-D16D8CB61040

P2093

Q33968358-1ACB2BF7-C9E3-4B83-8190-C6FD0A5E288F

Q33968358-21FAAEC2-282D-4505-8C85-E592B681D918

Q33968358-2D0B1460-3333-408A-B6D7-174A2C4DEA7C

Q33968358-48BDD6A4-7C7B-457F-96E9-691F59963A1E

Q33968358-4F1A48E4-F036-4B57-9FB1-C06DCE217319

Q33968358-58231DB4-FA50-42F2-849B-FB36216C90BB

Q33968358-8005F600-62FA-48B1-B2F9-12042510D2AF

Q33968358-A012FD3D-EDAE-454A-922B-2407D1E79D2D

Q33968358-A41D166D-98FB-4112-A222-34DBA74E2204

Q33968358-AA627773-C479-42EB-907E-25F064E900C1

P2860

Q33968358-0A11D94C-CC63-4FD6-B43B-881838BB2252

Q33968358-148A6188-E4DB-4648-A666-5052DE24FFAC

Q33968358-27D64822-0ABC-45C8-BEF8-22BB77027E48

Q33968358-2D7EE9AD-8686-40A9-8569-448EB7B88EA0

Q33968358-42353045-EAD9-4274-85A4-2079D37B68EB

Q33968358-4972D3C8-3BAB-4ACC-952A-436360023D74

Q33968358-76098D97-450B-4007-A2F1-2BFE1B514B18

Q33968358-8B20BF60-EC03-46CB-847A-908DF0EB24DF

Q33968358-91253465-ABAC-428B-8C61-2141C95D99C0

Q33968358-9E2F2713-5C57-4077-B94B-EF617E6D51BC

P304

Q33968358-13FA2885-B9F1-4791-B844-777B66E2D361

P31

Q33968358-FE238D68-3310-42D4-B484-AD43A43CA836

P356

Q33968358-1080666B-C6E3-425B-88AE-91300CA2AB71

P407

Q33968358-689D3100-3FAF-4C83-BF0F-D0808C0136D1

P433

Q33968358-33380E4B-9D91-41F4-B306-8C60BACA9FF0

P478

Q33968358-AD6342E5-7BBC-4F5E-85A4-E7E1AA35D481

P50

Q33968358-C088C202-EE60-4194-BDA7-63835F1A6F3E

P577

Q33968358-273F4935-E069-4EEE-B33E-90C59D8730F8

P5875

Q33968358-3533215D-C89E-409C-8C8F-4748D9AF18BE

P698

Q33968358-7B1540E4-A3B5-4CF4-B791-CC7AB225D51F

P921

Q33968358-18009DBE-8AC4-4B11-B59D-F992DA3DF4CF

P932

Q33968358-8A94D764-D63D-40BC-8B59-F9370CAF42A2

P356

P1433

P1476

Randomized controlled study of ...... and HIV infection: ACTG A5127.

@en

P2093

ACTG Protocol A5127 Team

http://www.w3.org/2001/XMLSchema#string

Beverly Alston-Smith

http://www.w3.org/2001/XMLSchema#string

Bruce Polsky

http://www.w3.org/2001/XMLSchema#string

Carol L Brosgart

http://www.w3.org/2001/XMLSchema#string

James F Rooney

http://www.w3.org/2001/XMLSchema#string

Janet Andersen

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Jacobson

http://www.w3.org/2001/XMLSchema#string

Kenneth E Sherman

http://www.w3.org/2001/XMLSchema#string

Marion G Peters

http://www.w3.org/2001/XMLSchema#string

Patrick Lynch

http://www.w3.org/2001/XMLSchema#string

P2860

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia.

Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment.

Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.

P304

1110-1116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.21388

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Susan Swindells

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6738234

http://www.w3.org/2001/XMLSchema#string

P698

17058225

http://www.w3.org/2001/XMLSchema#string

P921

P932

4114764

http://www.w3.org/2001/XMLSchema#string